Arcus Biosciences(RCUS)

HAYWARD, CABiotechnology7 H-1B visas (FY2023)

Focus: Arcus Biosciences is a publicly traded oncology-focused biotechnology company developing cancer immunotherapies, with a pipeline concentrated in checkpoint inhibitors and immuno-oncology combinations.

Oncology

Profile data last refreshed 4h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Arcus Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Arcus Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$117M

Pipeline & Clinical Trials

Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement

Hip Replacement Arthroplasty

N/A

Clinical Trials (1)

NCT01394744Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement

N/A

Help build intelligence for Arcus Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

R&D-driven culture with 291% R&D intensity and 12 pipeline programs across oncology indications, indicating significant technical depth and intellectual challenge.
Public company stability (ticker RCUS) with demonstrated H1B sponsorship (7 approvals, 0 denials in 2023) supporting visa-sponsored talent.
Recent partnership validation: Bristol-Myers Squibb collaboration on kidney cancer combination announced July 2026, signaling clinical progress and industry credibility.

Watch Out For

Severe cash burn: $340M R&D spend against only $117M FY2025 revenue, with $307M net loss and dwindling cash runway ($150M), creating restructuring risk within 12-18 months.
Zero commercial-stage products and no topProducts revenue; entire value dependent on pipeline execution with 55% of programs in Phase 1, indicating 5-7+ years to any potential approval.

Generated by Claude from Arcus Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

IPI-549

Triple-Negative Breast Cancer

Phase 1

Clinical Trials (1)

NCT03719326A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1

AB680

Pancreatic Cancer

Phase 1

Clinical Trials (3)

NCT03677973A Study to Investigate the Safety of AB680 in Healthy Volunteers

Phase 1

NCT04104672A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Phase 1

NCT04575311A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

Phase 1

zanzalintinib

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT06191796Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Phase 1

AB102

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT07662057A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants

Phase 1

AB801

Advanced Cancer

Phase 1

Clinical Trials (2)

NCT06004921A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

Phase 1

NCT06120075A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Phase 1

AB598

Advanced Cancer

Phase 1

Atezolizumab

Prostate Cancer

Phase 2

domvanalimab

Hepatobiliary Cancer

Phase 2

etrumadenant

Non-small Cell Lung Cancer

Phase 2

Clinical Trials (5)

NCT05915442Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Phase 2

NCT05024097A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Phase 2

NCT04791839Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Phase 2

+2 more

zimberelimab

Hepatobiliary Cancer

Phase 3

Clinical Trials (5)

NCT05724563Domvanalimab and Zimberelimab in Advanced Liver Cancers

Phase 2

NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Phase 2

NCT07283848Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Phase 2

+2 more

quemliclustat

Pancreatic Cancer

Phase 3

Clinical Trials (2)

NCT07667335Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

Phase 1/2

NCT07364214Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

Phase 1

casdatifan

Renal Cell Carcinoma

Phase 3

Clinical Trials (4)

NCT07011719Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase 3

NCT05999513A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

Phase 1

NCT06919991Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

Phase 1

+1 more

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 33 clinical trials

Top TAs: Oncology

H-1B (2023): 7 approvals

Publications: 27 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

24 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$117M4%

R&D Spend

$340M(291%)18%

Net Income

-$307M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature

2026

PMID:42386974

The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Arcus Biosciences(RCUS)

About Arcus Biosciences

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Arcus Biosciences(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Research Publications(10)